Cantoni Therapeutics

Cantoni Therapeutics is an early-stage biotech developing a novel class of bisubstrate small molecule inhibitors against the enzyme NNMT, a target implicated in metabolic dysregulation and cancer. The company's lead programs are in pre-clinical development for cardiometabolic disorders, aiming to address root causes of conditions like type 2 diabetes and obesity where current treatments often fall short. Founded in 2021 and based in Amsterdam, Cantoni is a private, pre-revenue company building a management team and advancing its proprietary platform.

Platform of bisubstrate small molecule inhibitors targeting both the nicotinamide (NA) and S-adenosyl methionine (SAM) binding pockets of the enzyme Nicotinamide N-methyltransferase (NNMT). Designed for potency and insensitivity to fluctuating substrate concentrations in the disease microenvironment.

The cardiometabolic therapeutic area is dominated by large pharma and biotech companies with approved drugs. Direct competition in the NNMT inhibitor space appears limited but may include other early-stage biotechs or academic spin-outs. Cantoni's key competitive claim is the superior mechanism of its bisubstrate inhibitors compared to earlier NA-competitive compounds.